In: Biotechnology
One Giant Leap Too Far, Why CRISPR is in the News
The title reads: “Easy DNA Editing Will Remake the World. Buckle Up.” From the outset this article in July’s Wired magazine…
Read MoreRare Diseases: The Role of Social Media in Patient Recruitment
Since the passing of the Orphan Drug Act in 1983, the rate of drug development in the United States has seen…
Read MoreWant More Cures? Modernize Clinical Trials
As the federal government creates a plan to speed the pace of drug development in the U.S., one specialty contract research…
Read MoreLab Tools and Ancient Sea Life: Medicine’s Lust for a Crab’s Blood
In the pharmaceutical and biomedical industries, the horseshoe crab is nothing short of a celebrity. If you haven’t heard about this…
Read More2014 FDA Drug Approvals at 18-year High, but How Much New Ground Are We Breaking?
As the New Year bells chimed in 2015, the curtains drew shut on this century’s best year for novel-drug approvals. The…
Read MoreWhat You Cared About in 2014
As the year closes, one can’t help but reflect. So, we take a look back at our most popular blog posts…
Read MoreThe J.P. Morgan Healthcare Conference: Worth the Fuss?
Attendance is by invitation only. There’s no trade show floor. And, good luck tracking down information on speakers and schedules if…
Read MoreUsability: Making Better Websites with Dead Simple User Experience
Let’s get something straight: We’re all marketing to humans. Yes, customers’ perspectives, experiences and industries may differ — even within the…
Read MoreTop 10 Biotech IPOs of 2014: West Coast Dominates
What was the most successful biotech IPO of 2014? Look no further than Ultragenyx. A special report by Fierce Biotech says…
Read MoreReplacing Adderall: Medicines to Change the World (Part I)
It’s a sad beginning to my series on medications set to change society and the way we live our lives. Shares…
Read More